Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma

被引：12

作者：

Machiraju, Devayani ^{[1
,2
]}

Schaefer, Sarah ^{[3
]}

Hassel, Jessica C. ^{[1
,2
]}

机构：

[1] Univ Hosp Heidelberg, Dept Dermatol, D-69120 Heidelberg, Germany

[2] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany

[3] Heidelberg Univ, Univ Heidelberg Hosp, Dept Dermatol, D-69120 Heidelberg, Germany

来源：

LIFE-BASEL | 2021年 / 11卷 / 12期

关键词：

age; melanoma; immunotherapy; tumor antigenicity; Tregs; gender; gut microbiome; stress; radiation; vaccination; IMMUNE CHECKPOINT INHIBITOR; CELL LUNG-CANCER; GUT MICROBIOTA; METASTATIC MELANOMA; DNA-DAMAGE; T-CELLS; COMBINATION THERAPY; CHOICE CHEMOTHERAPY; ANTITUMOR IMMUNITY; COMBINED NIVOLUMAB;

D O I：

10.3390/life11121318

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. However, in contrast to this hypothesis, recent studies in patients with metastatic melanoma have demonstrated that immunotherapy, especially with anti-PD1 treatment, is less effective in patients below 65 years, on average, with significantly lower responses and reduced overall survival compared to patients above 65 years of age. Besides, data on young patients are even more sparse. Hence, in this review, we will focus on age-dependent differences in the previously described resistance mechanisms to the treatment and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1 or PDL1 treatment in young melanoma patients.

引用

页数：17

共 50 条

[21] Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy [J].

Hossain, Sultana Mehbuba ;

Gimenez, Gregory ;

Stockwell, Peter ;

Weeks, Robert ;

Almomani, Suzan ;

Jones, Gregory T. ;

Ratajska, Magdalena ;

Shuen, Mathew ;

Bhat, Basharat ;

Rys, Janusz ;

Cybulska-Stopa, Bozena ;

Harazin-Lechowska, Agnieszka ;

Rodger, Euan ;

Jackson, Christopher ;

Chatterjee, Aniruddha ;

Eccles, Michael R. .

CANCER LETTERS, 2025, 618

[22] Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients [J].

Ohuchi, Kentaro ;

Kambayashi, Yumi ;

Hidaka, Takanori ;

Fujimura, Taku .

FRONTIERS IN ONCOLOGY, 2021, 11

[23] Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients [J].

Eikenes, Grethe ;

Liszkay, Gabriella ;

Balatoni, Timea ;

Czirbesz, Kata ;

Hunyadi, Karen ;

Kozeki, Zsofia ;

Kispal, Mihaly Tamas ;

Baranyai, Fanni ;

Danyi, Timea ;

Bocs, Katalin ;

Kenessey, Istvan .

CANCERS, 2023, 15 (15)

[24] Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges [J].

Moreira, Rita S. ;

Bicker, Joana ;

Musicco, Felice ;

Persichetti, Agnese ;

Pereira, Andre M. P. T. .

LIFE SCIENCES, 2020, 240

[25] Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy [J].

Carbone, Maria Luigia ;

Capone, Alessia ;

Guercio, Marika ;

Reddel, Sofia ;

Silvestris, Domenico Alessandro ;

Lulli, Daniela ;

Ramondino, Carmela ;

Peluso, Daniele ;

Quintarelli, Concetta ;

Volpe, Elisabetta ;

Failla, Cristina Maria .

FRONTIERS IN IMMUNOLOGY, 2023, 14

[26] Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond [J].

Fazel, Mina ;

Dufresne, Armelle ;

Vanacker, Helene ;

Waissi, Waisse ;

Blay, Jean-Yves ;

Brahmi, Mehdi .

CANCERS, 2023, 15 (06)

[27] Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD1 therapy [J].

Galus, Lukasz ;

Michalak, Michal ;

Lorenz, Mateusz ;

Stoinska-Swiniarek, Renata ;

Tusien Malecka, Daria ;

Galus, Agnieszka ;

Kolenda, Tomasz ;

Leporowska, Ewa ;

Mackiewicz, Jacek .

CANCER, 2023, 129 (13) :2047-2055

[28] Original Research Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy [J].

Dearden, Helen ;

Au, Lewis ;

Wang, Daniel Y. ;

Zimmer, Lisa ;

Eroglu, Zeynep ;

Smith, Jessica L. ;

Cuvietto, Marcello ;

Khoo, Chloe ;

Atkinson, Victoria ;

Lo, Serigne ;

V. Long, Georgina ;

Sandhu, Shahneen ;

Ascierto, Paolo A. ;

Carlino, Matteo S. ;

Johnson, Douglas B. ;

Larkin, James ;

Menzies, Alexander M. .

EUROPEAN JOURNAL OF CANCER, 2021, 153 :168-178

[29] PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma [J].

Luke, Jason J. ;

Ott, Patrick A. .

ONCOTARGET, 2015, 6 (06) :3479-3492

[30] Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy [J].

Chunhua Wang ;

Quan Chen ;

Meiqing Chen ;

Sizhen Guo ;

Ping Hou ;

Yulian Zou ;

Jun Wang ;

Bailin He ;

Qiuyu Zhang ;

Lieping Chen ;

Liqun Luo .

Cancer Immunology, Immunotherapy, 2023, 72 :1685-1698

← 1 2 3 4 5 →